Discovery of highly potent covalent SARS-CoV-2 3CLpro inhibitors bearing 2-sulfoxyl-1,3,4-oxadiazole scaffold for combating COVID-19-Reference-Cited by-同舟云学术

Discovery of highly potent covalent SARS-CoV-2 3CLpro inhibitors bearing 2-sulfoxyl-1,3,4-oxadiazole scaffold for combating COVID-19

Published:2023-11 Issue: Volume:260 Page:115721
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Zhang Fu-Mao,Huang Ting,Wang Feng,Zhang Gui-Shan,Liu Donglan,Dai Jun,Zhang Jian-Wei,Li Qing-Hua,Lin Guo-Qiang,Gao Dingding^ORCID,Zhao Jincun,Tian Ping

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference49 articles.

1. ISARIC4C investigators, Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study;Docherty;BMJ,2020

2. Comorbidities, multimorbidity and COVID-19;Russell;Nat. Med.,2023

3. Post-COVID-19 syndrome: epidemiology, diagnostic criteria and pathogenic mechanisms involved. Síndrome post-COVID-19: epidemiología, criterios diagnósticos y mecanismos patogénicos implicados;Carod-Artal;Rev. Neurol.,2021

4. Application of traditional Chinese medicine in treating COVID-19;Liu;Chin. Med. Cult,2021

5. Preventing COVID-19 with Chinese medicine: concepts and suggestions;Ochs;Chin. Med. Cult.,2020

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive investigation of the synthesis, spectral, DFT, and optical properties of a novel oxadiazolyl-pyrano[3,2-c]quinoline for photosensor applications;Journal of Molecular Structure;2024-12

2. How many organic small molecules might be used to treat COVID-19? From natural products to synthetic agents;European Journal of Medicinal Chemistry;2024-11

3. N-acylbenzimidazoles as selective Acylators of the catalytic cystein of the coronavirus 3CL protease;European Journal of Medicinal Chemistry;2024-10

4. Model informed dose regimen optimizing in development of leritrelvir for the treatment of mild or moderate COVID-19;Frontiers in Pharmacology;2024-08-28

5. A SAR and QSAR study on 3CLpro inhibitors of SARS-CoV-2 using machine learning methods;SAR and QSAR in Environmental Research;2024-07-02